Melinta Therapeutics

Company Listings from SPi: Melinta Therapeutics

You are here: Home >> SPi Company Listings >> Melinta Therapeutics

 

Melinta Therapeutics

Website:
http://

Search for other references to "melinta" on SPi News

Latest Melinta Therapeutics News

Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam) NEW HAVEN, Conn., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to trea...... 13:00 GMT Tuesday 27th November 2018

Melinta Therapeutics Reports Third Quarter 2018 Financial Results NEW HAVEN, Conn., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company, developing and commercializing novel antibiotics to tre...... 12:00 GMT Wednesday 7th November 2018

UPDATE - Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors NEW HAVEN, Conn., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antib...... 21:16 GMT Wednesday 31st October 2018

Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors NEW HAVEN, Conn., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antib...... 20:05 GMT Wednesday 31st October 2018

Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP NEW HAVEN, Conn., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antib...... 12:00 GMT Monday 29th October 2018

Melinta Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018 NEW HAVEN, Conn., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antib...... 13:00 GMT Friday 26th October 2018

Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer NEW HAVEN, Conn., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc., (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antib...... 13:00 GMT Monday 22nd October 2018

Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program NEW HAVEN, Conn., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibi...... 13:00 GMT Friday 5th October 2018

Melinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere™ (meropenem and vaborbactam) NEW HAVEN, Conn., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel anti...... 13:00 GMT Tuesday 2nd October 2018

Melinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries NEW HAVEN, Conn. and FLORENCE, Italy, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commerc...... 13:15 GMT Monday 1st October 2018

Buy Melinta Therapeutics
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us